# Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)

> **NCT01037764** · PHASE2 · TERMINATED · sponsor: **Asan Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Acute Lymphoid Leukemia

## Interventions

- **PROCEDURE:** alloHCT

## Key facts

- **NCT ID:** NCT01037764
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2014-12
- **Final completion:** 2016-12
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037764, "Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01037764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*